What is the market doing?
What the tape says about ALNY
Alnylam Pharmaceuticals, Inc. is −45% over the past year while the S&P 500 is +23%: 68 points behind the market.
−45%
1-year return · S&P 500 +23%
- vs 200-day average
- −29%
vs 200-day average · a clear downtrend
- RSI (14)
- 68
RSI (14) · neutral
- Below its 52-week high
- −51%
Below its 52-week high
Details›
- Last close2026-08-26
- $239.03
- 1 monthS&P 500 +3.7%
- −11%
- 1 yearS&P 500 +23%
- −45%
- 5 yearsS&P 500 +87%
- +34%
- vs 50-day average$264.86
- −9.8%
- 52-week high
- $491.22
- 52-week low
- $216.46
- Annualised volatility
- 44%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-06-30
- −$16M
| Year | Return |
|---|---|
| 2026 (year to date) | −40% |
| 2025 | +69% |
| 2024 | +23% |
| 2023 | −19% |
| 2022 | +40% |
| 2021 | +30% |
| 2020 | +13% |
| 2019 | +58% |
| 2018 | −43% |
| 2017 | +239% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 5 of 10 | +0.62% |
| Feb | 10 | 4 of 10 | +0.03% |
| Mar | 10 | 4 of 10 | +1.2% |
| Apr | 10 | 2 of 10 | −3.1% |
| May | 10 | 6 of 10 | +1.0% |
| Jun | 10 | 8 of 10 | +14% |
| Jul | 11 | 6 of 11 | +4.6% |
| Aug | 11 | 9 of 11 | +8.8% |
| Sep | 10 | 4 of 10 | +0.18% |
| Oct | 10 | 4 of 10 | −8.9% |
| Nov | 10 | 8 of 10 | +10% |
| Dec | 10 | 3 of 10 | −3.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
Ranks #57 of 145 by Smart Score